Nacho Aguilo

Recent developments in tuberculosis vaccines.

ESX-1-induced apoptosis during mycobacterial infection: to be or not to be, that is the question.

Pulmonary Mycobacterium bovis BCG vaccination confers dose-dependent superior protection compared to that of subcutaneous vaccination.

A human dendritic cell-based in vitro model to assess Mycobacterium tuberculosis SO2 vaccine immunogenicity.

A specific polymorphism in Mycobacterium tuberculosis H37Rv causes differential ESAT-6 expression and identifies WhiB6 as a novel ESX-1 component.

Elucidating sources and roles of granzymes A and B during bacterial infection and sepsis.

Hyper-attenuated MTBVAC erp mutant protects against tuberculosis in mice.

Mouse cytotoxic T cell-derived granzyme B activates the mitochondrial cell death pathway in a Bim-dependent fashion.

Human NK cells activated by EBV(+) lymphoblastoid cells overcome anti-apoptotic mechanisms of drug resistance in haematological cancer cells.

Klebsiella pneumoniae survives within macrophages by avoiding delivery to lysosomes.

Pulmonary but Not Subcutaneous Delivery of BCG Vaccine Confers Protection to Tuberculosis-Susceptible Mice by an Interleukin 17-Dependent Mechanism.

Safety of human immunisation with a live-attenuated Mycobacterium tuberculosis vaccine: a randomised, double-blind, controlled phase I trial.

Evaluation of the immunogenicity and diagnostic interference caused by M. tuberculosis SO2 vaccination against tuberculosis in goats.

MTBVAC vaccine is safe, immunogenic and confers protective efficacy against Mycobacterium tuberculosis in newborn mice.

Granzyme A Is Expressed in Mouse Lungs during Mycobacterium tuberculosis Infection but Does Not Contribute to Protection In Vivo.